A5021111881- Antibiotic Use and Resistance
- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Antimicrobial Resistance in Staphylococcus
- Bacterial Identification and Susceptibility Testing
- Infective Endocarditis Diagnosis and Management
- Streptococcal Infections and Treatments
- Urinary Tract Infections Management
- Pneumocystis jirovecii pneumonia detection and treatment
- Nosocomial Infections in ICU
- Antifungal resistance and susceptibility
- Clostridium difficile and Clostridium perfringens research
- Orthopedic Infections and Treatments
- Opioid Use Disorder Treatment
- Drug-Induced Adverse Reactions
- Pediatric Urology and Nephrology Studies
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections
- Neutropenia and Cancer Infections
- Tuberculosis Research and Epidemiology
- Surgical site infection prevention
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical Practices and Patient Outcomes
- Patient Satisfaction in Healthcare
Henry Ford Hospital
2016-2025
Eugene Applebaum College of Pharmacy and Health Sciences
2016-2025
Wayne State University
2016-2025
Henry Ford Health System
2017-2025
University of Tennessee at Knoxville
2017-2024
Knoxville College
2020-2024
University of Tennessee Health Science Center
2017-2023
University of Tennessee Medical Center
2017-2023
Alcoa (United States)
2022
Albany College of Pharmacy and Health Sciences
2011-2014
Abstract Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown. Methods A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated either polymyxin aminoglycoside-based regimens for infections...
Abstract Objective: To compare the incidence of surgical site infection (SSI) between cefazolin 3 g and 2 prophylaxis in patients weighing ≥120 kg that undergo elective colorectal surgery. Methods: A multicenter, retrospective cohort study was performed utilizing a validated database surgeries Michigan acute care hospitals. Adults who received metronidazole for 7/2012 6/2021 were included. The primary outcome SSI, which defined as an diagnosed within 30 days following principal operative...
ABSTRACT Non-tuberculosis mycobacteria (NTM) are extensively drug-resistant organisms that require long-term therapy. The study purpose was to quantify the incidence of and risk factors for antimycobacterial-associated adverse drug events (ADEs) in persons with NTM infections receiving outpatient A multicenter, retrospective cohort performed who received antimycobacterial treatment from 2013 2024. Inclusion criteria were age ≥18 years, ≥1 month treatment, follow-up visit within 3 months...
Objectives Infective endocarditis (IE) with non-HACEK Gram-negative (GN) organisms is rare, but associated poor outcomes. The purpose of this study was to quantify the microbiology, treatment strategies, and frequency outcomes in patients GN IE. Materials Retrospective cohort adults definite IE from 1/11-1/19. primary endpoint patient outcome, defined as a composite all-cause death or infection-related readmission within 90-days index infection. Results 43 were included: 51% men, median...
We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
Abstract Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority infections pulmonary origin (7/12; 58.3%). median (interquartile range) duration OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three experienced possible adverse effect while on therapy.
Multi-drug resistant gram-negative bacteria present a significant global health threat. Cefiderocol (CFDC), siderophore cephalosporin, has shown potential in combating this threat, but with the currently available data, its role therapy remains poorly defined. This multi-center, retrospective cohort study evaluated real-world application of CFDC across six U.S. medical centers from January 2018 to May 2023. Patients aged ≥18 years and who had received ≥72 hours were included. The primary...
Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly those barriers to discharge or who require prolonged parenteral antibiotic courses. A retrospective cohort study was performed provide further multicenter real-world evidence on use a sequential therapy for BSI. One hundred fifteen received BSI, defined any positive blood culture diagnosed infective endocarditis, from 13 centers geographically spread...
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB Clinical success occurred in 70.0% patients. Mortality and recurrence at 30 days 7.5% 12.5%, respectively. One patient experienced a probable rash due to MEV.
Limited data suggest that serious infections caused by Enterobacterales with a moderate to high risk of clinically significant AmpC production can be successfully treated cefepime if the minimum inhibitory concentration (MIC) is ≤2 µg/mL. However, isolates cefepime-susceptible dose-dependent (SDD) MIC 4-8 µg/mL should receive carbapenem due target attainment and extended-spectrum β-lactamase (ESBL) concerns.This was retrospective cohort study hospitalized patients E. cloacae, K. aerogenes,...
The Department of Health and Human Services (DHHS) HIV treatment guidelines recommend that antiretroviral regimens for treatment-naïve individuals include at least 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus either (1) a nonnucleoside inhibitor (NNRTI), (2) protease (PI), or (3) raltegravir, an integrase strand transfer inhibitor. Differences in drug-drug interaction potential may represent important differentiating feature when choosing between these regimen types.To identify...
Abstract Background Diabetic foot infections (DFIs) are commonly associated with antibiotic overuse. Empiric DFI treatment often includes coverage for Pseudomonas aeruginosa (PsA), but the frequency of PsA DFIs is poorly understood. The study objectives were to quantify prevalence and determine predictors DFIs. Methods This multicenter, retrospective cohort included hospitalized patients from 2013 through 2020 who age ≥18 years; diabetes mellitus diagnosis; based on International...
Forty-six patients were treated with eravacycline (ERV) for Acinetobacter baumannii infections, where 69.5% of isolates carbapenem resistant (CRAB). Infections primarily pulmonary (58.3%), and most received combination therapy (84.4%). The median (IQR) ERV duration was 6.9 days (5.1 to 11.1). Thirty-day mortality 23.9% in the cohort 21.9% CRAB patients. One patient experienced an ERV-possible adverse event.
The Centers for Disease Control and Prevention (CDC) categorized carbapenem-resistant Enterobacterales (CRE) infections as an "urgent" health care threat requiring public attention research. Certain patients with CRE may be at higher risk poor clinical outcomes than others. Evidence on or protective factors are warranted in order to determine the most at-risk populations, especially newer beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotics available treat CRE. We aimed identify...
ABSTRACT Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical microbiological outcomes addition associated adverse effects of eravacycline used hospitals. Real-world, observational involving patients receiving ≥72 h at 19 medical centers located all 5 regions United States between October 2018 August 2022. The primary outcome was success, defined as survival absence recurrence 30 days from end therapy...
Abstract Background Recent literature suggests ceftriaxone as a viable treatment of low-risk AmpC-producing organisms, allowing for the preservation AmpC-stable therapies moderate to high-risk organisms. This study aimed determine whether is effective in patients with bloodstream infections (BSI) caused by AmpC harboring Enterobacterales compared therapies. Methods was an IRB-approved, retrospective cohort hospitalized ≥18 years old BSI due Serratia marcescens, Morganella morganii, or...
Abstract Background Carbapenem-resistant Enterobacterales (CRE) are a major public health threat due to increasing prevalence and limited effective treatment options. Meropenem/vaborbactam (M/V) is beta-lactam/beta-lactamase inhibitor agent designed treat CRE. There paucity of data related patient characteristics associated outcomes with the utilization M/V in pneumonia The objective this study was describe real-world experience setting. Methods This retrospective, observational,...
Abstract Background Vancomycin plus an antipseudomonal β-lactam is used as lung transplant surgical prophylaxis, but optimal post-operative duration not defined. The study objective was to assess the impact of a shortened antibacterial infection prophylaxis (SIP) on nephrotoxicity in recipients. Table 1 Variables associated with AKI Methods IRB approved quasi experiment recipients who received SIP from 1/1/2016-9/30/2020 (pre-group) 10/1/2020-7/31/24 (post-group). Intervention:...